The association of Cytokine /chemokine profiles with the clinical outcome and safety in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone

Not Applicable

• Conditions: Multiple myeloma

• Registration Number: JPRN-UMIN000022213
• Lead Sponsor: Hamamatsu University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-11
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1.Previous treatment with lenalidomide 2.Hypersensitivity to lenalidomide and/or dexamethasone 3.non-secretory myeloma, solitary plasmacytoma, plasma cell leukemia, of POEMS syndrome 4.Positivity of HBs antigen or, HCV or HIV antibody 5.Uncontrollable liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, hypertension and infection 6.Double cancer requiring treatments 7.Psychoneurotic disorder, depression state or history 8.Patients with pregnancy, patients who may be pregnant, or patients during lactation 9.Pulomonary fibrosis, interstitial pneumonitis or interstitial shadow on chest CT, even if no symptom 10.Ineligible patient by physicians decision

Study & Design

• Study Type: Interventional
• Study Design: Not specified